Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC - Trial NCT05974007
Access comprehensive clinical trial information for NCT05974007 through Pure Global AI's free database. This phase not specified trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Recruiting. The study focuses on Non-Small Cell Lung Cancer. Target enrollment is 1500 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Timeline & Enrollment
N/A
Jan 01, 2022
Jun 01, 2026
Primary Outcome
Disease-free survival(DFS),Pathological Complete Response (pCR)
Summary
Despite the clinical success of immune checkpoint blockade (ICB), in neoadjuvant setting,
 there is still a lack of valid data for operable NSCLC in the real world. This study aim to
 compare the clinical outcomes (pathologic response rate versus survival) of neoadjuvant
 immunochemotherapy with neoadjuvant chemotherapy in the real world, to explore the impact of
 clinicopathological factors on clinical outcomes in neoadjuvant immunochemotherapy setting,
 and to identify potential neoadjuvant immunochemotherapy beneficiaries.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05974007
Non-Device Trial